FCP
BSX icon

Fidelis Capital Partners’s Boston Scientific BSX Stock Holding History

Fidelis Capital Partners’s Portfolio BSX Stock Details BSX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.08M Buy
17,273
+177
+1% +$14.2K 0.08% 201
2025
Q4 		$1.63M Buy
17,096
+404
+2% +$39.6K 0.12% 141
2025
Q3 		$1.63M Sell
16,692
-76
-0.5% -$7.87K 0.13% 139
2025
Q2 		$1.73M Buy
16,768
+239
+1% +$24.2K 0.16% 113
2025
Q1 		$1.68M Sell
16,529
-1
-0% -$101 0.18% 102
2024
Q4 		$1.7M Buy
16,530
+2,621
+19% +$231K 0.17% 106
2024
Q3 		$1.22M Sell
13,909
-1,199
-8% -$94.5K 0.14% 126
2024
Q2 		$1.11M Buy
15,108
+1,263
+9% +$92.4K 0.16% 115
2024
Q1 		$948K Buy
13,845
+809
+6% +$52K 0.14% 136
2023
Q4 		$754K Buy
13,036
+4,138
+47% +$221K 0.17% 124
2023
Q3 		$470K Buy
8,898
+788
+10% +$41.3K 0.16% 137
2023
Q2 		$439K Sell
8,110
-292
-3% -$15.3K 0.16% 143
2023
Q1 		$433K Buy
+8,402
New +$396K 0.18% 132

Other funds holding BSX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelis Capital Partners's BSX Position: Q1 2026 in Review

Fidelis Capital Partners increased its Boston Scientific (BSX) stake by 1% in Q1 2026, buying an estimated $14.2K and bringing the position to 17,273 shares worth $1.08M. The position accounts for 0.08% of the portfolio, ranked #201.

Fidelis Capital Partners first reported a position in BSX in Q1 2023 and has held it in 13 quarters since. The position peaked at $1.73M in Q2 2025. 1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.

  • Fidelis Capital Partners held 17,273 shares of Boston Scientific worth $1.08M as of Q1 2026.
  • Fidelis Capital Partners bought 177 Boston Scientific shares in Q1 2026, an estimated $14.2K.
  • Boston Scientific made up 0.08% of Fidelis Capital Partners's portfolio in Q1 2026, its #201 holding.
  • Fidelis Capital Partners first reported a position in Boston Scientific in Q1 2023 and has held it in 13 quarters since.
  • Fidelis Capital Partners's Boston Scientific position peaked at $1.73M in Q2 2025.
  • 1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.

Based on Fidelis Capital Partners's 13F filing for Q1 2026, filed 6 May 2026.